CEFVAC-B Vaccine (Hepatitis B Vaccine (rDNA) I.P. (Genetically Engineered))

Table of Content

Hepatitis B virus (HBV) infection is a serious global health problem, with 350 million suffering from chronic hepatitis B worldwide.1 India accounts for a 10– 15 % of the entire global pool of HBV carriers (40 million). One million Indians are at risk of getting HBV infection, and about 100,000 deaths occur due to HBV infection. 2 HBV is responsible for 70% of chronic hepatitis and 80% of liver cirrhosis cases in India. It may even be linked to a large burden of liver cancer.3

Hepatitis B is spread through contact with an infected person’s blood and body fluids. All those who are not vaccinated against the infection are potentially at risk. Since 2002, the Hepatitis B vaccine has been a part of India’s Universal Immunization Programme. This vaccine is able to protect around 95% of recipients from developing Hepatitis B. The vaccine is given in three doses that include a zero dose (first dose), a second dose after one month of the first dose and a third dose after 6 months of the first dose. The vaccine can protect the recipient from this infection for decades. In addition, it is may help to bring down the number of cases of liver cirrhosis and liver cancer.

Cipla Ltd. has signed an agreement with Serum Institute of India Private Limited (SII) to market CEFVAC- B, a hepatitis B vaccine, for adults in India. CEFVAC-B is indicated for active immunization against Hepatitis-B in adults at risk of exposure to HBV-positive material. It  is recommended for individuals at risk of HBV by sexual exposure, individuals who are at risk for infection by percutaneous injections and mucosal exposures to blood ( drug users, household contacts of HBV positive persons, residents and staff of facilities for disabled persons, health care and public safety workers, persons with end-stage renal diseases, and individuals requiring blood transfusions) and individuals with chronic liver diseases, HIV infection, and all individuals seeking protection from HBV virus.

The key features of the vaccine include,

  • High immunogenicity and low reactogenicity4
  • Achieves 100% seroconversion in adult Indians5
  • Thiomersal free vaccine
  • Safe and well tolerated 4,5

The introduction of CEFVAC-B for adult immunization against HBV, will help prevent transmission of a deadly disease like Hepatitis B.


  1. J Viral Hepat. 2004;11(2):97-107.
  2. Hepatology, Medicine and Policy 2017 2:6.
  3. Gut. 1996; 38(Suppl 2): S56–S59.
  4. Vaccine 2006;24(17):3457-60.
  5. Indian J Med Microbiol. 2004;22(1):34-8. 



Each dose of 1 ml contains:-

20 mcg of purified Hepatitis B surface antigen

Adsorbed on Aluminium hydroxide (Al+++) 0.50 mg to 0.80 mg

Thiomersal Free

Produced in Hansenula polymorpha (yeast)

Dosage Form

Ampoule for intramuscular injection



CEFVAC-B (Hepatitis - B Vaccine (rDNA) I.P.) is a non-infectious recombinant DNA Hepatitis B Vaccine. It contains purified surface antigen of the virus obtained by culturing genetically-engineered Hansenula polymorpha yeast cells having the surface antigen gene of the Hepatitis B virus. The Hepatitis B surface antigen (HBsAg) expressed in the cells of Hansenula polymorpha is purified through several chemical steps and formulated as a suspension of the antigen adsorbed on aluminium hydroxide. The vaccine does not contain any material of human or animal origin.


CEFVAC-B is indicated for active immunisation against hepatitis B infection in subjects considered at risk of exposure to HBV-positive material. Immunisation against hepatitis B is expected in the long term to reduce not only the incidence of this disease, but also its chronic complications such as chronic active hepatitis B and hepatitis B associated cirrhosis and primary hepatocellular carcinoma.

In areas of low prevalence of hepatitis B, immunisation with CEFVAC-B is recommended for neonates/infants and adolescents as well as for subjects who are, or will be, at increased risk of infection such as.

  • Health Care Personnel.
  • Patients receiving frequent blood products.
  • Personnel and residents of institution.
  • Persons at increased risk due to their sexual behavior.
  • Illicit users of addictive injectable drugs.
  • Travellers to areas with a high endemicity of HBV.
  • Infants born of mothers who are HBV carries.
  • Persons originating from areas with a high endemicity of HBV.
  • Others: Police personnel, fire brigade personnel, armed forces personnel and anybody who through their work or personal lifestyle may be exposed to HBV.
  • Household contacts of any of the above groups and of patients with acute or chronic HBV infection.

In areas of intermediate or high prevalence of hepatitis B, with most of the population at risk of acquiring the disease, immunisation should be offered to all neonates and young children. Immunisation should also be considered for adolescents and young adults. The vaccine can be safely and effectively given simultaneously but at different injection site with DTP, DT, TT, BCG, Polio vaccine (OPV and IPV), yellow fever vaccine, Haemophilus influenzae type b and vitamin A supplementation.

Dosage and Administration

Adult dose vaccine: 20 mcg dose (in 1.0 ml suspension) is recommended for adults aged 20 years and above.

Preparation for Administration

CEFVAC-B should be injected intramusculary in the deltoid region in adults and children or in the anterolateral thigh in neonates, infants and young children. The vaccine may be administered subcutaneously in patients with thrombocytopenia or bleeding disorders. The vaccine should be well shaken before use. Only sterile needle and syringes should be used for each injection.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.

Do not administer this product intravenously or intradermally.

Recommended Dose and Schedule

Primary Immunisation. A series of three intramuscular injections is required to achieve optimal protection.

The following immunisation schedules can be recommended:

  • 6, 10, 14 weeks for infants
  • 0, 1, 6 months
  • 0, 1, 2 months (rapid schedule)

The immunisation schedule should be adapted to meet local immunisation recommendations.

Booster dose

The need for the booster dose in healthy individuals who have received the full primary immunization, is not recommended. It would seem advisable to recommend a booster dose when Anti-HBs antibody titres fall below 10 IU/L for all people at risk and especially for patients who are immunocompromised (HIV infected patients) or those on haemodialysis.

Special Dosage Recommendations

Dosage recommendation for neonates born of mothers who are HBV carriers

The 0, 1, 2 month immunisation schedule is recommended, and should start at birth. Concomitant administration of Hepatitis B immunoglobulin not necessary, but when Hepatitis B immunoglobulin is given simultaneously with CEFVAC-B a separate injection site must be chosen.

Dosage recommendation for known or presumed exposure of HBV

In circumstances where exposure to HBV has recently occurred (e.g. needles stick with contaminated needle) the first dose of CEFVAC-B can be administered simultaneously with Hepatitis B immunoglobulin which however must be given at a separate injection site. The rapid immunisation schedule should be advised.

Dosage recommendation for immunocompromised persons

The primary immunisation schedule for chronic haemodialysis patients or persons who have an impaired immune system is four doses of 40 mcg at 0, 1, 2 and 6 months from the date of first dose. The immunisation schedule should be adapted in order to ensure that the anti-HBs antibody titre remains above the accepted protective level of 10 IU/L.


CEFVAC-B should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous Hepatitis B Vaccine administration.

Warnings and Precautions

Because of the period of latency of hepatitis B infection it is possible for unrecognised infection to be present at the time of immunisation. The vaccine may not prevent hepatitis B infection in such cases. The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E and other pathogens known to infect the liver. The immune response to Hepatitis B vaccines is related to age. In general, people over 40 years of age respond less well.

In haemodiaysis patients and persons with an impaired immune system, adequate anti-HBs antibody titres may not be obtained after the primary immunisation course and such patients may therefore require administration of additional doses of vaccine (see Dosage recommendation for Immunocompromised persons)

As with all injectable vaccines, appropriate medication (e.g. adrenaline) should always be readily available for treatment in case of rare anaphylactic reactions following the administration of the vaccine. ADRENALINE INJECTION (1:1000) MUST BE IMMEDIATELY AVAILABLE SHOULD AN ACUTE ANAPHYLACTIC REACTION OCCUR DUE TO ANY COMPONENT OF THE VACCINE. For treatment of severe anaphylaxis the initial dose of adrenaline is 0.1 - 0.5 mg (0.1 - 0.5 ml of 1:1000 injection) given s/c or i/m. Single dose should not exceed 1 mg (1 ml). For infants and children the recommended dose of adrenaline is 0.01 mg/kg (0.01 ml/kg of 1:1000 injection). Single paediatric dose should not exceed 0.5 mg (0.5 ml). The mainstay in the treatment of severe anaphylaxis is the prompt use of adrenaline, which can be lifesaving. It should be used at the first suspicion of anaphylaxis.

As with the use of all vaccines, those vaccinated should remain under observation for not less than 30 minutes for possibility of occurrence of immediate or early allergic reactions. Hydrocortisone and antihistaminics should also be available in addition to supportive measures such as oxygen inhalation.

Special care should be taken to ensure that the injection does not enter a blood vessel.

CEFVAC-B should not be administered in the gluteal muscle or intradermally since this may result in a lower immune response.

CEFVAC-B may be used to complete a primary immunisation course started either with plasma-derived or with other genetically-engineered hepatitis B vaccines, or as a booster dose in subjects who have previously received a primary immunisation course with plasma-derived or with other genetically-engineered hepatitis B vaccines.

Undesirable Effects

The undesirable events are temporally related to the administration of Hepatitis B Vaccine. They are usually mild and confined to the first few days of the vaccination. The most common reactions are mild soreness, erythema, induration, fatigue, fever, malaise, influenza-like symptoms.

Less common systemic reactions include nausea, vomiting, diarrhoea, abdominal pain, abnormal liver function tests, arthralgia, mystalgia, rash, pruritus, urticaria, liver function.

Storage and Handling Instructions

CEFVAC-B should be stored between 2° and 8°C. Not to be frozen. Discard if vaccine has been frozen.

Packaging Information

CEFVAC-B: 1 ml…. 1 Dose Ampoule (Adult)

Last updated: May 2016

Last reviewed: June 2017